TB006
Alzheimer's Disease
Key Facts
About TrueBinding
TrueBinding is a private, clinical-stage biotech developing a novel therapeutic platform centered on inhibiting Galectin-3, a master regulator of chronic inflammation and age-related decline. Its lead candidate, TB006, has shown early signals of efficacy in a Phase 1b/2a Alzheimer's trial and is advancing into Phase 2 studies for both Alzheimer's and Parkinson's, supported by an FDA-authorized Expanded Access Program. The company's strategy positions it at the intersection of neurodegeneration and the broader biology of aging, aiming to address multiple chronic diseases with a single biologic mechanism. With a lean, experienced leadership team and a platform validated by recent foundational science awards, TrueBinding is pursuing a high-risk, high-reward path in a field of significant unmet need.
View full company profileAbout TrueBinding
TrueBinding is a private, clinical-stage biotech developing a novel therapeutic platform centered on inhibiting Galectin-3, a master regulator of chronic inflammation and age-related decline. Its lead candidate, TB006, has shown early signals of efficacy in a Phase 1b/2a Alzheimer's trial and is advancing into Phase 2 studies for both Alzheimer's and Parkinson's, supported by an FDA-authorized Expanded Access Program. The company's strategy positions it at the intersection of neurodegeneration and the broader biology of aging, aiming to address multiple chronic diseases with a single biologic mechanism. With a lean, experienced leadership team and a platform validated by recent foundational science awards, TrueBinding is pursuing a high-risk, high-reward path in a field of significant unmet need.
View full company profileAbout TrueBinding
TrueBinding is a private, clinical-stage biotech developing a novel therapeutic platform centered on inhibiting Galectin-3, a master regulator of chronic inflammation and age-related decline. Its lead candidate, TB006, has shown early signals of efficacy in a Phase 1b/2a Alzheimer's trial and is advancing into Phase 2 studies for both Alzheimer's and Parkinson's, supported by an FDA-authorized Expanded Access Program. The company's strategy positions it at the intersection of neurodegeneration and the broader biology of aging, aiming to address multiple chronic diseases with a single biologic mechanism. With a lean, experienced leadership team and a platform validated by recent foundational science awards, TrueBinding is pursuing a high-risk, high-reward path in a field of significant unmet need.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |